Silence Therapeutics Plc, which is developing siRNA-based therapies and a delivery platform, reported that its half-year revenue for the period ended June 2008 fell to £124,338 from £1,268,837 a year earlier. However, it said that its turnover for the full year would be similar to the £4 million sales it generated in 2007, “thereby ensuring a healthy year-end cash balance.”
